<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102562">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01954160</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00047050</org_study_id>
    <secondary_id>5U10HL084904</secondary_id>
    <nct_id>NCT01954160</nct_id>
  </id_info>
  <brief_title>Study of Renal Denervation in Patients With Heart Failure</brief_title>
  <acronym>PRESERVE</acronym>
  <official_title>Promotion of Renal Sodium Excretion by Renal Sympathetic Denervation in Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adrian Hernandez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Congestive heart failure is a common disorder in which the heart cannot pump enough blood to
      meet the needs of the rest of the body.  Poor sodium handling by the kidneys is a damaging
      effect of heart failure, and it leads to symptoms of congestion such as shortness of breath
      or ankle swelling.  Recent studies suggest that reducing  the nerve activity to a kidney
      could reduce sodium retention and blood pressure. An improvement in the way the kidneys
      handle sodium may reduce disease progression and decrease symptoms for heart failure
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Urine Sodium Excretion</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Within-subject comparison of increase in urine sodium excretion following saline loading before RSD and 13 weeks following RSD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine volume</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urine volume following furosemide therapy after sodium loading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour urine sodium excretion</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Difference in 24-hour urine sodium excretion, compared between pre-RSD and 13 weeks after RSD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimated GFR by creatinine and cystatin C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cystatin C</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BUN level</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance from 24-hour urine creatinine</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine albumin</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urine albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Resistive Index</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Intra-renal hemodynamics as measured by Renal Resistive Index (RRI) by renal Doppler ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end systolic volume</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Echo: Left ventricular end systolic volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Echo: Left Ventricular Ejection Fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global longitudinal strain</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Echo: Global longitudinal strain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV end systolic dimension (LVESd)</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Echo: LV end systolic dimension (LVESd)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV end diastolic dimension (LVEDd)</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Echo: LV end diastolic dimension (LVEDd)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Atrial size</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Echo: Left Atrial size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma N-terminal pro-brain natriuretic peptide</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting plasma norepinephrine</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting urine norepinephrine</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma renin activity</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma aldosterone</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Test</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire Score</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Functional Classification</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Heart rate variability indices by Holter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue Doppler indices</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Echo: Tissue Doppler indices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular End Diastolic Volume</measure>
    <time_frame>13 Weeks following Renal Denervation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Echo: Left Ventricular End Diastolic Volume</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Early Renal Denervation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects undergo renal denervation within 2 weeks of baseline visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Renal Denervation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects undergo renal denervation within 2 weeks of Week 13 visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Symplicity Renal Denervation System</intervention_name>
    <arm_group_label>Early Renal Denervation</arm_group_label>
    <arm_group_label>Late Renal Denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 21-80 years old.

          -  History of chronic HF (&gt;6 months) with current NYHA II-III symptoms.

          -  LVEF ≤40% on a clinically indicated echocardiogram obtained within 6 months prior to
             informed consent.

          -  Requires daily loop diuretic (≥40mg furosemide per day, or equivalent) to maintain
             euvolemia (absence of congestive signs including jugular venous distension with JVP &gt;
             7cm H20, ≥ moderate (2+) peripheral edema, S3).

          -  Optimized medical therapy for HF. Patients will be receiving guideline-recommended
             therapy (per the 2013 ACCF/AHA HF Guidelines) including angiotensin-converting enzyme
             (ACE) inhibitors and/or angiotensin receptor blocker, beta-blockers, and aldosterone
             antagonists without changes in heart failure medication regimen (including diuretics)
             for previous 14 days.

          -  Systolic blood pressure (BP) ≥110 mmHg at time of informed consent.

          -  Able to maintain stable medications for 52 weeks.

          -  Suitable renal artery anatomy for RSD procedure. All of the following criteria must
             be met, based on the screening renal Doppler ultrasound:

          -  ≥ 20mm treatable length in each renal artery,

          -  Diameter in treatable segments must be ≥4mm,

          -  Lone main renal vessel feeding each kidney.

        Exclusion Criteria:

          -  Unable to comply with protocol or procedures.

          -  Evidence of orthostatic hypotension or known dysautonomia. Orthostatic hypotension is
             defined by ≥1 of the following feature(s) within 2-5 minutes of quiet standing:

          -  ≥ 20 mmHg fall in systolic pressure

          -  ≥ 10 mmHg fall in diastolic pressure

          -  Symptoms of cerebral hypoperfusion (e.g. dizziness or lightheadedness, visual
             blurring or darkening of the visual fields, syncope).

          -  Evidence of or history of renal artery stenosis, nephrectomy, or renal transplant.

          -  Significant renal impairment as defined by estimated glomerular filtration rate
             (eGFR) &lt; 45 ml/min/1.73m2 determined by MDRD equation.

          -  Significant proteinuria (&gt;2g protein/daily protein excretion).

          -  Body mass index (BMI) &gt;35 kg/m2.

          -  Acute coronary syndrome within last 4 weeks as defined by ECG changes and biomarkers
             of myocardial necrosis (e.g. troponin) in an appropriate clinical setting (chest
             discomfort or angina equivalent).

          -  Coronary revascularization procedures (percutaneous coronary intervention or cardiac
             artery bypass graft) and or valve surgery within 30 days of screening or expected
             procedures within the next 6 months.

          -  Cardiac resynchronization therapy, with or without implantable cardiac defibrillator
             within 90 days of screening or expected procedures within the next 6 months.

          -  Hypertrophic or restrictive cardiomyopathy, constrictive pericarditis, active
             myocarditis, active endocarditis, or complex congenital heart disease.

          -  Severe advanced HF, with ANY of the following features:

          -  Current or anticipated use of ventricular assist device within the next 6 months.

          -  Current or anticipated IV vasoactive drug therapy for HF management within the next 6
             months.

          -  Listed cardiac transplant candidate, with transplantation likely within the next 6
             months.

          -  Known allergic reactions to iodinated radiological contrast media or iodinated
             antiseptics.

          -  Greater than moderate mitral or aortic stenosis, and/or severe tricuspid
             regurgitation.

          -  Terminal illness (other than HF) with expected survival of less than 1 year.

          -  Female who is pregnant, nursing, or of childbearing potential not practicing
             effective birth control.

          -  Enrollment or planned enrollment in another clinical trial within the next 12 months.

          -  History of urinary outflow tract obstruction, bladder retention and/ or moderate to
             severe prostate hypertrophy.

          -  History of adrenal insufficiency

          -  History of untreated hypothyroidism

          -  Patients with non-cardiac dyspnea or fatigue due to frailty, motivational factors,
             pulmonary disease or orthopedic problems that precludes them from performing 6MWT.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugene Braunwald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Snell</last_name>
      <email>gail.snell@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Javed Butler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Anello</last_name>
      <email>manello@partners.org</email>
    </contact>
    <investigator>
      <last_name>Michael Givertz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane Cocca-Spofford</last_name>
      <email>dcoccaspofford@partners.org</email>
    </contact>
    <investigator>
      <last_name>Marc Semigran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gail Jamieson</last_name>
      <email>gjamieson@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Gordon Huggins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janet Gatzke</last_name>
      <email>gatzke.janet@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Margaret Redfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Flanagan</last_name>
      <email>jflanaga@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Mann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Adams</last_name>
      <email>patricia.adams@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Felker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Fonk</last_name>
      <email>fonkt@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Wilson Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randall Starling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Health System</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Dettmer</last_name>
      <email>mdettmer@metrohealth.org</email>
    </contact>
    <investigator>
      <last_name>Mark Dunlap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marisa Konig</last_name>
      <email>marisa.konig@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Margulies, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Gallagher</last_name>
      <email>barbara.gallagher@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>David Whellan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Vermont - Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michaelanne Rowen</last_name>
      <email>michaelanne.rowen@vtmednet.org</email>
    </contact>
    <investigator>
      <last_name>Martin LeWinter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>September 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University Medical Center</investigator_affiliation>
    <investigator_full_name>Adrian Hernandez</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
